阿托伐他汀对急性冠脉综合征患者血清MMP-9及IL-18的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (556 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of atorvastatin on plasma MMP-9 and IL-18 in patients with acute coronary syndrome (ACS). Methods Sixty patients with ACS were randomly divided into treatment group (taking atorvastatin 20 mg/d for 14 days), control group (no atorvastatin, other treatments were similar to treatment group). Before drug therapy and after 14 days, MMP-9 and IL-18 levels in serum were measured. Results Compared with pre-treatment, the levels of MMP-9 and IL-18 in treatment group were decreased [(295±110)mg/L vs(358±95)mg/L;(399±115)pg/ml vs(471±105)pg/ml ,respectively],these differences were statistically significant (P<0.05). Moreover, the levels of MMP-9 and IL-18 in treatment group were significantly lower than those in control group [(358±95)mg/L,(466±109)pg/ml, respectively], these differences were statistically significant (P<0.05). Conclusions Atorvastatin can decrease serum MMP-9 and IL-18 levels in patients with ACS, which contributes to inhibit plaque inflammation, to advance the stability of plaque. Early intensive atorvastatin treatment may yield more significant benefits to the patients with ACS.

Key words： acute coronary syndrome atorvastatin matrix metalloproteinase-9 interleukin-18

Received: 31 March 2014

ZTFLH:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2014/V25/I9/905

[5]	Gracie J A,Robertson S E,Mclnnes I B. Interleukin-18[J]. J Leukoc Biol,2003,73(2):213-224.
[1]	Davl G, Tuttolomondo A,Santilli F,et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke[J]. J Atheroscler Thromb,2009,16( 6):707-713.
[2]	Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis [J]. J Lipid Res,2009,50 (Suppl):S352-357.
[6]	Mallat Z,Corbaz A,Scoazec A,et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability [J]. Circulation,2001,104(14):598-1603.
[3]	Pedersen T R,Cater N B,Faergeman O,et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction from the incremental decrease in end points through aggressive lipid lowering [IDEAL] trial [J]. Am J Cardiol,2010,106 (3):354-359.
[7]	Hong M K,Mintz G S,Lee C W,et al. Ruptures in stable angina pectoris compared with acute coronary syndrome[J]. Int J Cardiol,2007,114( 1):78-82.
[4]	Cho E J,Min Y J,Oh M S,et al. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia [J]. Am J Cardiol,2011,107(5):793-796.
[8]	Xu S,Tang L,Mi Y, et al. Clinical significance of leukotriene b4 and extracellular matrix metalloproteinase inducer in acute coronary syndrome [J]. Clin Invest Med,2013,36(6):E282-289.
[5]	Gracie J A,Robertson S E,Mclnnes I B. Interleukin-18[J]. J Leukoc Biol,2003,73(2):213-224.
[9]	Galis Z S,Khatri J J. Matrix metalloproteinases in vascular remodering and athrogenesis: the good,the bad,and the ugly[J]. Circ Res,2002,90(3):251-262.
[6]	Mallat Z,Corbaz A,Scoazec A,et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability [J]. Circulation,2001,104(14):598-1603.
[7]	Hong M K,Mintz G S,Lee C W,et al. Ruptures in stable angina pectoris compared with acute coronary syndrome[J]. Int J Cardiol,2007,114( 1):78-82.
[8]	Xu S,Tang L,Mi Y, et al. Clinical significance of leukotriene b4 and extracellular matrix metalloproteinase inducer in acute coronary syndrome [J]. Clin Invest Med,2013,36(6):E282-289.
[9]	Galis Z S,Khatri J J. Matrix metalloproteinases in vascular remodering and athrogenesis: the good,the bad,and the ugly[J]. Circ Res,2002,90(3):251-262.
[10]	Kulach A,Dabek J,Glogowska-Ligus J,et al. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes [J]. Pharmacol Rep,2010,62(6):1108-1116.
[10]	Kulach A,Dabek J,Glogowska-Ligus J,et al. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes [J]. Pharmacol Rep,2010,62(6):1108-1116.
[11]	Empana J P,Canoui-Poitrine F,Luc G,et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome:the PRIME study [J]. Eur Heart J,2008,29(16):1966-1974.
[11]	Empana J P,Canoui-Poitrine F,Luc G,et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome:the PRIME study [J]. Eur Heart J,2008,29(16):1966-1974.
[12]	Nissen S E,Nichlls S J,Wolski K,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial[J]. JAMA,2008,299(13):1561-1573.
[12]	Nissen S E,Nichlls S J,Wolski K,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial[J]. JAMA,2008,299(13):1561-1573.
[13]	Ray K K,Cannon C P. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes [J]. J Am Coll Cardiol,2005,46(8):1425-1433.
[13]	Ray K K,Cannon C P. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes [J]. J Am Coll Cardiol,2005,46(8):1425-1433.
[14]	Parthan A I,Leahy K J,O’Sullivan A K,et al. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome [J]. Pharmacoeconomics, 2013,31(6):519-531.
[14]	Parthan A I,Leahy K J,O’Sullivan A K,et al. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome [J]. Pharmacoeconomics, 2013,31(6):519-531.
[15]	Dabek J,Kulach A,Gasior Z. The role of matrix metalloproeinases in acute coronary syndromes[J]. Eur J Intern Med,2007,18 ( 6):463-466.
[15]	Dabek J,Kulach A,Gasior Z. The role of matrix metalloproeinases in acute coronary syndromes[J]. Eur J Intern Med,2007,18 ( 6):463-466.